News

Patheon was selected to assist with the development of advanced INTAC based products including single-entity and fixed-dose combination solid oral dosage forms with immediate and modified release properties.

Under the collaboration, Rockland will provide and manage Formula’s specially hired preclinical research team. Further, Rockland will provide the classified research facilities for Formula’s preclinical development needs in

Following the redemption of a Priority Review Voucher with the submission, an FDA decision is anticipated in August 2016. Sanofi executive vice president of global diabetes & cardiovascular

33A is an antibody-drug conjugate (ADC) targeted to CD33 utilizing Seattle Genetics’ newest technology, comprising an engineered cysteine antibody (EC-mAb) stably linked to a highly potent DNA binding

The unrestricted grants will be awarded to organizations with a track record of excellence in results-driven research. Gilead Sciences executive vice president of research William Lee said: "For

ViiV Healthcare CEO Dominique Limet said: "As a result of these transactions, ViiV Healthcare now has one of the most robust HIV pipelines in the industry. "The assets

Under the terms of the deal, Unilife grants Amgen exclusive rights to its wearable injectors within select drug classes for use with certain Amgen drugs. Amgen will also

The sNDA includes findings from the phase 2 Terrain and Strive studies, to update the appropriate clinical sections within the existing indication. The FDA approved enzalutamide to treat

The phase 3 ONCEMRK study, which is assessing Isentress in earlier untreated HIV-1 infected adults, met its primary efficacy endpoint by demonstrating that 1200mg of Isentress once-daily was